74 related articles for article (PubMed ID: 7757994)
1. Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation.
Mayr GA; Reed M; Wang P; Wang Y; Schweds JF; Tegtmeyer P
Cancer Res; 1995 Jun; 55(11):2410-7. PubMed ID: 7757994
[TBL] [Abstract][Full Text] [Related]
2. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity.
Unger T; Sionov RV; Moallem E; Yee CL; Howley PM; Oren M; Haupt Y
Oncogene; 1999 May; 18(21):3205-12. PubMed ID: 10359526
[TBL] [Abstract][Full Text] [Related]
3. Specific DNA binding by p53 is independent of mutation at serine 389, the casein kinase II site.
Rolley N; Milner J
Oncogene; 1994 Oct; 9(10):3067-70. PubMed ID: 8084615
[TBL] [Abstract][Full Text] [Related]
4. Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo.
Jamal S; Ziff EB
Oncogene; 1995 Jun; 10(11):2095-101. PubMed ID: 7784054
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of bovine leukemia virus Tax protein is required for in vitro transformation but not for transactivation.
Willems L; Grimonpont C; Kerkhofs P; Capiau C; Gheysen D; Conrath K; Roussef R; Mamoun R; Portetelle D; Burny A; Adam E; Lefèbvre L; Twizere JC; Heremans H; Kettmann R
Oncogene; 1998 Apr; 16(17):2165-76. PubMed ID: 9619825
[TBL] [Abstract][Full Text] [Related]
6. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression.
Fiscella M; Ullrich SJ; Zambrano N; Shields MT; Lin D; Lees-Miller SP; Anderson CW; Mercer WE; Appella E
Oncogene; 1993 Jun; 8(6):1519-28. PubMed ID: 8502477
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes.
Lohrum M; Scheidtmann KH
Oncogene; 1996 Dec; 13(12):2527-39. PubMed ID: 9000127
[TBL] [Abstract][Full Text] [Related]
8. Signaling to p53: breaking the posttranslational modification code.
Appella E; Anderson CW
Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
[TBL] [Abstract][Full Text] [Related]
9. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
11. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
12. p53 must be competent for transcriptional regulation to suppress tumor formation.
Nistér M; Tang M; Zhang XQ; Yin C; Beeche M; Hu X; Enblad G; van Dyke T; Wahl GM
Oncogene; 2005 May; 24(22):3563-73. PubMed ID: 15750633
[TBL] [Abstract][Full Text] [Related]
13. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element.
Zhang W; Guo XY; Deisseroth AB
Oncogene; 1994 Sep; 9(9):2513-21. PubMed ID: 8058314
[TBL] [Abstract][Full Text] [Related]
14. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage.
Jimenez GS; Bryntesson F; Torres-Arzayus MI; Priestley A; Beeche M; Saito S; Sakaguchi K; Appella E; Jeggo PA; Taccioli GE; Wahl GM; Hubank M
Nature; 1999 Jul; 400(6739):81-3. PubMed ID: 10403253
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between site-specific modifications on p53 and histone H3.
Warnock LJ; Adamson R; Lynch CJ; Milner J
Oncogene; 2008 Mar; 27(11):1639-44. PubMed ID: 17891183
[TBL] [Abstract][Full Text] [Related]
16. Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53.
Turenne GA; Paul P; Laflair L; Price BD
Oncogene; 2001 Aug; 20(37):5100-10. PubMed ID: 11526498
[TBL] [Abstract][Full Text] [Related]
17. A single serine residue at position 375 of VP16 is critical for complex assembly with Oct-1 and HCF and is a target of phosphorylation by casein kinase II.
O'Reilly D; Hanscombe O; O'Hare P
EMBO J; 1997 May; 16(9):2420-30. PubMed ID: 9171355
[TBL] [Abstract][Full Text] [Related]
18. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
19. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential.
Mundt M; Hupp T; Fritsche M; Merkle C; Hansen S; Lane D; Groner B
Oncogene; 1997 Jul; 15(2):237-44. PubMed ID: 9244359
[TBL] [Abstract][Full Text] [Related]
20. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
Shivakumar CV; Das GC
Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
